Research ArticleCancer

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

See allHide authors and affiliations

Science Signaling  29 Mar 2016:
Vol. 9, Issue 421, pp. ra33
DOI: 10.1126/scisignal.aac8460
PDF Container

Navigate This Article